Open Therapeutics

Drug and Therapeutic development


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

At the heart of our vision is Therapoid®: an online crowdsourcing community that allows stakeholders from across the therapeutic development community to come together, share knowledge and access technologies that will drive the next generation of therapeutic and healthcare innovation. There are no other platforms like it; it is in an Internet space where life science researchers around the world can openly exchange information at no charge on the platform.

The skyrocketing cost of healthcare is one of the great challenges of our time. At Open Therapeutics we’re answering the call, using crowdsourcing as an engine to drive down the cost of therapeutic research and development and usher in a new era of accessibility and affordability in the life science industry in the United States -- and beyond.

Life science is a multi-billion industry in the United States -- but it’s an industry in desperate need of an upgrade.  

For decades, two facts have reigned supreme when it comes to drug development: drug development is slow and it is expensive. A 2014 report from Tufts University found that it costs $2B and takes more than 12 years to bring a pharmaceutical to the market.Further compounding the challenge is the uncertainty that each new drug is faced with. 93% of drugs that start development never make it to market -- placing tremendous pressure on the drugs that do make it to pay for the investment in the ones that don’t.

But the people who end up paying the price are the end consumers -- people who depend on these therapies for their health and often their lives. The cost of drug development drives up the cost of healthcare, and the direction of innovation is driven, not by which therapies are most needed, but by which therapies can most quickly recoup the cost of development.

For decades, these conditions have been accepted as facts -- immutable realities of the therapeutic landscape. But at Open Therapeutics, we got to thinking: are they really? What would happen if we challenged the status quo of therapeutic development, stripped out the secrecy and restored a spirit of collaboration and communication to the way therapeutics are developed? How would that impact the time to market, the cost of development -- and, as a result, the cost to the end consumer?

These are the questions that drive the development of Open Therapeutics. If you’re interested in knowing the answers, we should talk.

The Open Therapeutics mission is simple: reintroduce communication and collaboration to the therapeutic development ecosystem as a way to drive down the cost of research and make life-saving therapies more affordable and accessible than ever before.

History has shown us time and time again that innovation thrives when lines of communication are open and knowledge is shared. At Open Therapeutics, we’re taking the spirit of open innovation and apply it to therapeutic development.

The result:

Open Therapeutics is tackling the therapeutic affordability challenge on two fronts: technology and product portfolio.

At the heart of the Open Therapeutics vision is Therapoid : our open-source collaboration platform for the healthcare and therapeutic community.

Therapoid is crowdsourcing at its best: an online open-source community where stakeholders from across the therapeutic development process can come together, share knowledge, and access information and technologies they can use to make the therapeutic development process more efficient and cost-effective.

At Open Therapeutics, we’re not just talking the talk when it comes to open collaboration -- we practice what we preach.

Over the past 7 years, the Open Therapeutics team has developed several technologies with the potential to transform therapeutic development. These technologies will be made freely available for scientific collaboration through the Therapoid platform, as engines to drive the next generation of therapeutic innovation.

Technologies currently available are genetically-enhanced bacteria (BactoBots™), viruses (ViruBots™), and Proteome Antibiotics™.

A joint effort of Open Therapeutics and Bacmine SL, the Proteome Antibiotics™ platform is focused on finding essential proteins required for pathogen survival. Researchers can target these essential proteins to develop therapeutic agents that will kill the pathogens. This includes even antibiotic resistant organisms.

Taken together, the Therapoid platform and Open Therapeutics’ own portfolio of biotechnologies represent the Open Therapeutics vision for the future of therapeutic development: innovation, driven by science and fueled by collaboration and openness.

This is an exciting time for Open Therapeutics, as we stand on the brink of launching a new era of innovation in the biotechnology space.

The Therapoid platform is currently under development, on pace for launch in 2017. Our portfolio of biotechnology products, which we’ve spent the past 7 years developing, will be freely available in our web platform.  

The Open Therapeutics team is honored to be collaborating  with leading institutions including:

Up next for Open Therapeutics: complete development of the Therapoid® platform. For more information about the future of Open Therapeutics and how you can be part of it, request access to the Business Plan tab of this profile, and let’s talk!

Jason Barkeloo - Founder & Executive Chairman
Jason has over thirty years of experience as a technology entrepreneur, researcher, investor, and educator. His undergraduate degree in Anthropology is from The Ohio State University. He has a Master’s of Education with biology sciences and social studies certifications from Antioch University. After a US Army career, Jason was an award earning science educator via the US Department of Defense Troops to Teachers program. As a patented inventor and author, Jason speaks about entrepreneurship, biotechnology, human/computer interface technologies, open business models, and intellectual property.

Jerome Hamilton - CEO
Jerome works tirelessly educating both the scientific and investment community on the importance of scientific collaboration free of constraints. Prior to his role as CEO, he was Senior Vice President of Global Operations at Stratasys where he focused on ensuring Global Operations supported aggressive corporate growth from both a strategic and tactical perspective. Prior to Stratasys, he was Vice President at 3M where he devised strategic and operational plans for 3M’s Industrial Business Group. He was also the leader of the company’s Masking and Surface Protection Business with full P&L responsibilities. Hamilton also has extensive experience in Lean Six Sigma Operations, Corporate Quality and Acquisition Integration.  Prior to 3M, he was plant manager at Ford Motor Company where he reversed declining productivity at one facility, making it the top-ranked plant among twenty Ford plants. Hamilton earned his Bachelor of General Science from Morehouse College, a Bachelor of Science in Industrial Engineering from Georgia Tech, and a Master of Science in Engineering Management from the University of Detroit Mercy. He also holds a Master of Science in International Logistics from Georgia Tech and has completed the Harvard Business School’s Advanced Management Program.

Jason Seifert - CFO / COO
Jason is a highly successful finance executive with more than 20 years of experience driving quantifiable achievements through precise financial management and company development within for-profit and nonprofit organizations alike. He has strong qualifications in developing and implementing financial controls and processes in addition to productivity improvements and change management. He has a proven success with increasing revenue and expanding market share while controlling expenses, and demonstrated ability to streamline business operations that drive growth and increase efficiency and bottom-line profit. Jason received his Bachelor of Science in Accounting from the University of Wisconsin-River Falls, and holds a Certified Public Accountant and Certified Management Accountant Certification.

David Krauth - Director, Software Development
David is an entrepreneurial software craftsman with over 20 years of professional experience in desktop, embedded, and web-based platforms. Early on in his career, David honed his skills with some of the giants in the software industry, such as Andersen Consulting (Accenture), IBM, and Microsoft, before pursuing his desire to work in smaller, agile environments, focused on innovation and rapid deployment. David has built a reputation for being passionate about technology in general and on open-source languages in particular. David has attended the University of Florida and Daytona State College

Dr. Li Guo - Director of Cellular Engineering and Community Manager
Dr. Li Guo joined Open Therapeutics in January 2014 as Director of Cellular Engineering. In the company, Dr. Guo leads the therapeutic MicrobialBots development. She works with a multi-disciplinary team and she collaborates with researchers from different fields. Dr. Guo has a broad experience in cell biology, neuroscience and cancer. Prior to her Open Therapeutics role, she studied neural-glial communication in health and diseases, using in vitro cultures and in vivo genetic animal models, as a research fellow at Cincinnati Children’s hospital Medical Center. Dr. Guo received her PhD from the Institute of Neuroscience, the Chinese Academy of Science in 2006 and her B.S. degree from Xiamen University in 2001.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2017 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.

// //